Mereo BioPharma (MREO) Announces Appointment of Dr. Abdul Mullick to Board of Directors May 17, 2022 08:03AM
Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors May 17, 2022 08:00AM
Alnylam to Webcast R&D Day Dec 8, 2016 04:00PM
Alnylam to Webcast Presentations at Upcoming November Investor Conferences Oct 31, 2016 04:00PM
Alnylam to Webcast Conference Call Discussing Third Quarter 2016 Financial Results Oct 26, 2016 04:00PM
View Older Stories

Sep 6, 2016 04:00PM Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Aug 2, 2016 04:00PM Alnylam to Webcast Presentation at Canaccord Genuity Growth Conference
Jul 25, 2016 08:00AM Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia (WFH) 2016 World Congress
Jun 27, 2016 08:00AM Alnylam to Report New Patisiran and Revusiran Results at the XV International Symposium on Amyloidosis
Jun 3, 2016 08:00AM Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data
May 31, 2016 04:00PM Alnylam to Webcast Presentations at Upcoming June Investor Conferences
Apr 26, 2016 04:00PM Alnylam to Webcast Presentations at Upcoming May Investor Conferences
Apr 25, 2016 04:00PM Alnylam to Webcast Conference Call Discussing First Quarter 2016 Financial Results
Apr 6, 2016 04:00PM Alnylam to Webcast Presentation at 15th Annual Needham Healthcare Conference
Feb 29, 2016 08:00AM Alnylam to Webcast Presentations at Upcoming March Investor Conferences
Feb 11, 2016 04:00PM Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period Progress
Feb 4, 2016 04:00PM Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2015 Financial Results
Feb 1, 2016 04:00PM Alnylam to Webcast Presentations at Upcoming February Investor Conferences
Feb 1, 2016 08:02AM Alnylam Pharma (ALNY) Completes Enrollment in APOLLO Phase 3 Study with Patisiran
Feb 1, 2016 08:00AM Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Jan 11, 2016 08:00AM Alnylam Outlines 2016 Goals for RNAi Therapeutics Pipeline
Jan 4, 2016 08:00AM Alnylam to Webcast Presentation at 34th Annual J.P. Morgan Healthcare Conference
Dec 29, 2015 04:00PM Alnylam to Webcast Presentation at Goldman Sachs “Healthcare CEOs Unscripted: A View from the Top” Conference
Dec 21, 2015 08:03AM Alnylam Pharma (ALNY) Files CTA for ALN-GO1 with U.K. MHRA
Dec 21, 2015 08:00AM Alnylam Files Clinical Trial Application (CTA) for ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
Dec 18, 2015 04:01PM Alnylam Pharma (ALNY) Appoints New Chairman
Dec 18, 2015 04:00PM Alnylam Announces Updates to Company’s Board of Directors Supportive of Transition Towards Commercial Stage
Dec 17, 2015 08:06AM Alnylam Pharma (ALNY) Announces Initiation of First Part of ALN-CC5 Phase 1/2
Dec 17, 2015 08:00AM Alnylam Initiates Dosing in PNH Patients in Phase 1/2 Clinical Trial for ALN-CC5
Dec 10, 2015 06:31AM Alnylam Pharma (ALNY) Plans Pipeline Update Across Three STArs
Dec 10, 2015 06:30AM Alnylam Pharmaceuticals to Present Path to “Alnylam 2020” at R&D Day
Dec 7, 2015 10:33AM Alnylam Pharma (ALNY) Announces Positive Data from Fitusiran Phase 1 as Hemophilia A, B Treatment
Dec 7, 2015 10:30AM Alnylam Reports Positive Phase 1 Study Results for Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) in Patients with Hemophilia A and B
Dec 6, 2015 09:00AM Alnylam Reports that ALN-CC5 Achieves Up to 99 Percent Knockdown of Serum C5 and Up to 98 Percent Inhibition of Serum Hemolytic Activity with Durability Supportive of Once Monthly and Possibly Once Qu
Dec 2, 2015 04:00PM Alnylam to Webcast R&D Day
Nov 23, 2015 04:00PM Alnylam to Webcast Presentations at Upcoming December Investor Conferences
Nov 11, 2015 10:45AM Alnylam Pharmaceuticals and The Medicines Company Announce that New ALN-PCSsc Results from Late-Breaking Presentation at American Heart Association Meeting Confirm Potential for Bi-Annual Hypercholest
Nov 9, 2015 07:00AM Alnylam Pharmaceuticals Reports Third Quarter 2015 Financial Results and Highlights from Recent Period
Nov 5, 2015 09:08AM Alnylam to Present New Clinical Results with Investigational RNAi Therapeutics at 57th Annual Meeting of the American Society of Hematology (ASH)
Nov 3, 2015 05:00AM Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension (OLE) Studies for Patisiran and Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR
Nov 2, 2015 04:00PM Alnylam to Webcast Presentations at Upcoming November Conferences
Nov 2, 2015 08:00AM Alnylam to Webcast Conference Call Discussing Third Quarter 2015 Financial Results
Oct 29, 2015 07:00AM Alnylam to Report New Clinical Results with Investigational RNAi Therapeutics for the Treatment of Transthyretin-Mediated Amyloidosis at the First European Congress on Hereditary ATTR Amyloidosis
Oct 14, 2015 07:00AM Alnylam Demonstrates Continued Commitment to Transthyretin-Mediated Amyloidosis Patients with Advancement of ALN-TTRsc02, an Investigational RNAi Therapeutic with Potential for Low Volume, Once Quarte
Oct 13, 2015 09:00AM Alnylam Advances New Innovations in RNAi Therapeutics
Oct 8, 2015 04:00PM Alnylam Initiates Phase 1 Open Label Extension (OLE) Study with ALN-AT3, an Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders
Oct 1, 2015 07:00AM Alnylam and Genzyme Announce that Genzyme Opts into ALN-AT3 Hemophilia Program for Development and Commercialization Outside of North America and Western Europe
Sep 28, 2015 02:47PM Alnylam Granted Summary Judgment by United States District Court for the District of Massachusetts in Tuschl II Patent Inventorship Dispute
Sep 28, 2015 08:00AM Alnylam and Collaborators Report First-Ever Evidence that Patisiran Reduces Pathogenic, Misfolded Transthyretin (TTR) Monomers and Oligomers in TTR-Mediated Amyloidosis (ATTR Amyloidosis) Patients wit
Sep 15, 2015 07:00AM Alnylam Reports Positive Initial Clinical Results for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias
Sep 10, 2015 04:00PM Alnylam to Webcast Presentations at Upcoming September Conferences
Sep 8, 2015 07:00AM Alnylam Accelerates Development of ALN-GO1, a Subcutaneously Administered Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
Aug 30, 2015 03:30AM ALN-PCSsc Achieves Quarterly and Potentially Bi-Annual Subcutaneous Dose Regimen Profile for Effective LDL-C Lowering in Phase 1 Clinical Study
Aug 6, 2015 04:00PM Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results and Highlights Recent Period Activities
Aug 5, 2015 04:00PM Alnylam to Webcast Presentation at Canaccord Genuity 35th Annual Growth Conference
View Older Stories